Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +441494 818 026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+441494 818 026

Testimonials
I have been dealing with Zenopa for quite a while and have found their services to be of the highest order. I found them to be informative, helpful, and knowledgeable in their field of expertise.
Alan, 2011

GlaxoSmithKline HPV vaccine shows anal cancer benefits

23 August 2011 00:00 in Pharmaceutical Company Product News


GlaxoSmithKline's bivalent human papillomavirus (HPV) vaccine Cervarix has shown efficacy against anal cancer in a new study.

An investigation led by US scientists and published in The Lancet has found that the drug can offer protection against HPV infections that lead to anal cancer.

The product was shown to offer particularly significant efficacy among patients who received the vaccine before exposure to the virus, which could be important both for women and homosexual males.

Cervarix is already commonly used as a routine vaccination treatment for girls against cervical cancer, targeting HPV types 16 and 18, while anal cancer is an increasingly common condition that is twice as likely to target females as males.

Diane Harper and Stephen Vierthaler from the University of Missouri-Kansas City School of Medicine said: "The additional protection against four oncogenic anal HPV types in women increases their benefits from vaccination."

Earlier this month, positive data was reported from a trial of GlaxoSmithKline and Impax Pharmaceuticals' new compound IPX066, which is intended for use against Parkinson's disease.ADNFCR-8000103-ID-800707675-ADNFCR

Other news stories from 23/08/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd